TMCI Q4 2025 Earnings Call Summary

Q4 Revenue: $62.5 million, down 9% year-over-year, primarily due to a shift towards lower-priced products.
Gross Margin: 80.6%, slightly down from 80.7% in Q4 2024.
Operating Expenses: Increased to $56.3 million from $55.7 million in Q4 2024, attributed to restructuring and litigation costs.
Net Loss: $9.4 million ($0.15 per share), compared to a loss of $0.5 million ($0.01 per share) in Q4 2024.
Adjusted EBITDA: $6.2 million, down from $11.1 million in Q4 2024. Full-year adjusted EBITDA loss was $3.9 million, a 64% improvement from the previous year.
Cash Position: $48.4 million in cash, with a new credit facility providing an additional $115 million in liquidity. Cash burn reduced to $27.3 million in 2025, down 46% from 2024.

TMCI is transitioning from a Lapiplasty-focused company to a comprehensive bunion solutions provider, launching multiple new bunion procedure innovations.
New product offerings include the Nanoplasty and Percuplasty 3D MIS systems, which target high-volume osteotomy segments, and the SpeedMTP system for arthritic patients.
The company has expanded its active surgeon base from nearly 1,300 in 2020 to over 3,300 in 2025.
TMCI plans to launch additional products in 2026, including the Lapiplasty Lightning platform and the Speed XM Fusion system, aimed at expanding its total addressable market (TAM).

2026 Revenue Guidance: Expected to be between $200 million and $212 million, reflecting a decline of 6% to flat compared to 2025.
Anticipated revenue declines in the first half of 2026, with expected growth in the fourth quarter driven by new product launches and improved case volumes.
Expected adjusted EBITDA loss in 2026 is projected to be between $4 million and $6 million, with a further reduction in cash usage by approximately 50%.

The overall foot and ankle market experienced softness in 2025, with deferrals of elective procedures impacting case volumes.
Revenue mix shift towards lower-priced products continues to be a headwind.
Competitive pressures remain as TMCI navigates a crowded market with various players.
The company faces uncertainty regarding macroeconomic conditions that could affect future performance.

Management acknowledged the softness in the foot and ankle market and indicated that while they are gaining share, the overall market dynamics remain challenging.
The success of the new MIS osteotomy products is critical for achieving revenue growth, with management expressing confidence in their adoption among surgeons.
The sales force is being trained to manage a broader product portfolio without losing focus on core bunion solutions.
There is optimism about the potential for increased surgeon adoption of new products, with early indications showing positive reception and integration into practices.

TMCI — Treace Medical Concepts, Inc.